Background The world has made great strides towards beating malaria, although about half
of the world population is still exposed to the risk of contracting malaria. Develo** an …

Malaria is a mosquito-borne disease caused by protozoan parasites of the genus
Plasmodium. Despite significant declines in malaria-attributable morbidity and mortality over …

Background Currently licensed and approved malaria subunit vaccines provide modest,
short-lived protection against malaria. Immunization with live-attenuated Plasmodium …

A highly protective malaria vaccine would greatly facilitate the prevention and elimination of
malaria and containment of drug-resistant parasites. A high level (more than 90%) of …

Summary Background Plasmodium falciparum sporozite (PfSPZ) Vaccine is a metabolically
active, non-replicating, whole malaria sporozoite vaccine that has been reported to be safe …

Vaccination with infectious Plasmodium falciparum (Pf) sporozoites (SPZ) administered with
antimalarial drugs (PfSPZ-CVac), confers superior sterilizing protection against infection …

Consistent, high-level, vaccine-induced protection against human malaria has only been
achieved by inoculation of Plasmodium falciparum (Pf) sporozoites (SPZ) by mosquito bites …

The global decline in malaria has stalled, emphasizing the need for vaccines that induce
durable sterilizing immunity. Here we optimized regimens for chemoprophylaxis vaccination …

A live-attenuated malaria vaccine, Plasmodium falciparum sporozoite vaccine (PfSPZ
Vaccine), confers sterile protection against controlled human malaria infection (CHMI) with …

The leading malaria vaccine in development is the circumsporozoite protein (CSP)-based
particle vaccine, RTS, S, which targets the pre-erythrocytic stage of Plasmodium falciparum …